Design and Validation of new TLR agonists for therapeutic vaccination in oncology

Forschungsstelle

INNOSUISSE

Projektnummer

17388.2 PFLS-LS

Projekttitel

Design and Validation of new TLR agonists for therapeutic vaccination in oncology: MIP: Amal Therapeutics

Projekttitel Englisch

Design and Validation of new TLR agonists for therapeutic vaccination in oncology: MIP: Amal Therapeutics

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	Design and Validation of new TLR agonists for therapeutic vaccination in oncology
Kurzbeschreibung (Englisch)	Design and Validation of new TLR agonists for therapeutic vaccination in oncology: MIP: Amal Therapeutics
Abstract (Deutsch)	Modulating the cancer patient own immune system, to allow the specificdestruction of the tumoral cells, is becoming an attractive approach in oncology. This can be achieved through therapeutic cancer vaccines. One essential component to mount an efficacious anti-tumor immunity are adjuvants. Toll Like Receptor (TLR) agonists have risen recently as promising adjuvants of cancer vaccines. The goal of this project is to design and validate novel peptide agonist of TLR .
Abstract (Englisch)	Modulating the cancer patient own immune system, to allow the specificdestruction of the tumoral cells, is becoming an attractive approach in oncology. This can be achieved through therapeutic cancer vaccines. One essential component to mount an efficacious anti-tumor immunity are adjuvants. Toll Like Receptor (TLR) agonists have risen recently as promising adjuvants of cancer vaccines. The goal of this project is to design and validate novel peptide agonist of TLR .